Skip to content
10-K

Annual Report

Aligos Therapeutics, Inc. ALGS

0001193125-26-092614

← back to feed
Filed
Mar 5, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted FY 2025 · Dec 31, 2025 9.88M sh
Shares Diluted FY 2025 · Dec 31, 2024 6.26M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$82.5M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$80.74M
Short Term Investments FY 2025 · Dec 31, 2025 $59.54M
Short Term Investments FY 2025 · Dec 31, 2024 $19.94M
Cash And Equivalents FY 2025 · Dec 31, 2025 $18.3M
Cash And Equivalents FY 2025 · Dec 31, 2024 $37M
Stockholders Equity FY 2025 · Dec 31, 2025 $53.55M
Stockholders Equity FY 2025 · Dec 31, 2024 −$28.97M
Stockholders Equity FY 2025 · Dec 31, 2023 $92.08M
Current Liabilities FY 2025 · Dec 31, 2025 $21.23M
Current Liabilities FY 2025 · Dec 31, 2024 $21.74M
Total Liabilities FY 2025 · Dec 31, 2025 $34.99M
Total Liabilities FY 2025 · Dec 31, 2024 $99.07M
Current Assets FY 2025 · Dec 31, 2025 $82.86M
Current Assets FY 2025 · Dec 31, 2024 $62.14M
Total Assets FY 2025 · Dec 31, 2025 $88.53M
Total Assets FY 2025 · Dec 31, 2024 $70.09M
Eps Diluted FY 2025 · Dec 31, 2025 −$2.45
Eps Diluted FY 2025 · Dec 31, 2024 −$20.94
Eps Basic FY 2025 · Dec 31, 2025 −$2.45
Eps Basic FY 2025 · Dec 31, 2024 −$20.94
Sga Expense FY 2025 · Dec 31, 2025 $20.72M
Sga Expense FY 2025 · Dec 31, 2024 $22.83M
Rd Expense FY 2025 · Dec 31, 2025 $69.45M
Rd Expense FY 2025 · Dec 31, 2024 $70.27M
Net Income FY 2025 · Dec 31, 2025 −$24.19M
Net Income FY 2025 · Dec 31, 2024 −$131.21M
Operating Income FY 2025 · Dec 31, 2025 −$87.99M
Operating Income FY 2025 · Dec 31, 2024 −$89.15M
Revenue FY 2025 · Dec 31, 2025 $2.19M
Revenue FY 2025 · Dec 31, 2024 $3.61M